Musculoskeletal science & practice · 2026
Economic evaluation alongside the multicenter randomized controlled ACTIVE trial: cost-effectiveness of an integrated personalized eHealth program for working-age knee arthroplasty patients.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Straat A Carlien, Kuijer P Paul F M, Strijbos Daniël O, Maarleveld Jantine M, van Dongen Johanna M, Huirne Judith A F, Kerkhoffs Gino M M J, Anema Johannes R, Coenen Pieter
Аннотация
PURPOSE: To evaluate cost-effectiveness of the ACTIVE intervention aimed at supporting working-age knee arthroplasty patients in resuming daily life activities.
METHODS: We performed an economic evaluation (societal and healthcare perspectives) alongside the multicenter randomized-controlled ACTIVE trial. Eligible patients were of working-age, awaiting knee arthroplasty, employed ≥8 h/week, and willing to return to work. Patients received usual care or the personalized ACTIVE intervention including the iRecover-app with activity tracker, case-manager consultation and goal attainment scaling. Cost and effects were measured up to one year postoperatively. Effects were expressed in quality-adjusted life years (QALYs) and recovery of daily life activities (PROMIS-PF). Resource use was self-reported and converted into euros according to the Dutch manual for costing.
RESULTS: Of 287 randomized knee arthroplasty patients (145 intervention, 142 control), 265 (92%) analyzed (132 intervention, 133 control). Intervention patients resumed activities on average 37 (95% confidence interval: -55-18] days earlier than controls, at an incremental cost of €34 per day. Albeit all non-statistically significant, while QALY gains were observed in the intervention group compared with the control group (mean 0.021,95%CI: -0.008-0.049), mean total societal costs were higher (€1491, -3349-6331), with a low to moderate probability (0.48) of cost-effectiveness from a societal perspective. Contrary, from a healthcare perspective, the intervention demonstrated a high probability (0.84) of being cost-effective at the Dutch willingness-to-pay threshold of €50,000/QALY.
CONCLUSION: The intervention led to earlier recovery of daily life activities and showed promising cost-effectiveness from a healthcare perspective. High absenteeism costs limited cost-effectiveness from a societal perspective.
TRIAL REGISTRATION: NL8525.
METHODS: We performed an economic evaluation (societal and healthcare perspectives) alongside the multicenter randomized-controlled ACTIVE trial. Eligible patients were of working-age, awaiting knee arthroplasty, employed ≥8 h/week, and willing to return to work. Patients received usual care or the personalized ACTIVE intervention including the iRecover-app with activity tracker, case-manager consultation and goal attainment scaling. Cost and effects were measured up to one year postoperatively. Effects were expressed in quality-adjusted life years (QALYs) and recovery of daily life activities (PROMIS-PF). Resource use was self-reported and converted into euros according to the Dutch manual for costing.
RESULTS: Of 287 randomized knee arthroplasty patients (145 intervention, 142 control), 265 (92%) analyzed (132 intervention, 133 control). Intervention patients resumed activities on average 37 (95% confidence interval: -55-18] days earlier than controls, at an incremental cost of €34 per day. Albeit all non-statistically significant, while QALY gains were observed in the intervention group compared with the control group (mean 0.021,95%CI: -0.008-0.049), mean total societal costs were higher (€1491, -3349-6331), with a low to moderate probability (0.48) of cost-effectiveness from a societal perspective. Contrary, from a healthcare perspective, the intervention demonstrated a high probability (0.84) of being cost-effective at the Dutch willingness-to-pay threshold of €50,000/QALY.
CONCLUSION: The intervention led to earlier recovery of daily life activities and showed promising cost-effectiveness from a healthcare perspective. High absenteeism costs limited cost-effectiveness from a societal perspective.
TRIAL REGISTRATION: NL8525.